TAIJI GROUP(SH:600129)2016-04-29 16:00Financial Performance - Operating revenue for the period was approximately CNY 1.699 billion, a decrease of 2.52% year-on-year[7]. - Net profit attributable to shareholders reached approximately CNY 919.7 million, a significant increase of 4,390.14% compared to the same period last year[7]. - Basic and diluted earnings per share were CNY 2.1544, an increase of 4,388.33% compared to the previous year[7]. - The company reported a net profit of approximately 635.35 million RMB, a significant recovery from a loss of about 284.35 million RMB in the previous period[23]. - Net profit for the period reached CNY 918,431,738.63, a substantial rise from CNY 43,205,719.68 in the previous year[27]. - The total comprehensive income for Q1 2016 was approximately ¥766.40 million, down by ¥24.27 million compared to the same period last year[30]. Assets and Liabilities - Total assets at the end of the reporting period were approximately CNY 9.996 billion, a decrease of 0.34% compared to the end of the previous year[7]. - The company's total liabilities decreased from approximately 8.723 billion RMB to about 8.348 billion RMB, a reduction of around 4.3%[23]. - Cash and cash equivalents decreased by 36.24%, a reduction of 854.13 million RMB, primarily due to decreases in the company's subsidiaries[13]. - Non-current liabilities due within one year decreased by 68.31%, a reduction of 191.11 million RMB, mainly due to the maturity and refinancing of these liabilities[14]. - Long-term borrowings increased by 91.64%, an increase of 90 million RMB, primarily due to increased loans from the subsidiary Southwest Pharmaceutical Co., Ltd.[15]. Shareholder Information - The total number of shareholders at the end of the reporting period was 34,506[11]. - The largest shareholder, Taiji Group Co., Ltd., held 38.81% of the shares, with 81.8 million shares pledged[11]. Cash Flow - The company reported a net cash flow from operating activities of approximately -CNY 117.6 million, a decrease of 438.95% compared to the previous year[7]. - Cash inflows from operating activities totaled approximately ¥2.52 billion, slightly up from ¥2.51 billion in the previous year[33]. - Cash outflows from operating activities amounted to approximately ¥2.63 billion, an increase from ¥2.48 billion in the previous year[33]. - The net cash flow from investing activities was approximately ¥154.25 million, compared to a negative cash flow of ¥71.46 million in the previous year[34]. - The ending cash and cash equivalents balance was approximately ¥422.84 million, down from ¥904.53 million in the previous year[34]. Investment and Restructuring - Non-operating income included a gain from the disposal of non-current assets amounting to approximately CNY 960.8 million[8]. - The company completed a significant asset restructuring involving its subsidiary Chongqing Tongjun Pavilion Co., Ltd., transferring 20% of its shares (54,926,197 shares) to China Energy Conservation and Environmental Protection Group Co., Ltd. for a total consideration of 300 million RMB and all of Tongjun Pavilion's divested assets[17]. - The company is focused on enhancing its profitability and scaling its pharmaceutical business through strategic asset management and restructuring initiatives[17]. Other Financial Metrics - The weighted average return on net assets increased by 68.13 percentage points to 70.13%[7]. - Investment income increased by 262,900.13%, an increase of 960.47 million RMB, primarily due to gains from the transfer of equity in Chongqing Tongjun Pavilion Co., Ltd.[16]. - Cash received from the disposal of subsidiaries and other operating units increased by 30 million RMB, mainly due to a major asset restructuring completed by the subsidiary Tongjun[16].